Search

Toggle navigation. Go. Tumor suppressor p53 fragments. Family. Domains. Species. 2.

25 Jul 2024: We focus on how mutation affects proteins in the cell cycle, particularly the tumour suppressor p53, in order to design novel anti-cancer drugs that function by restoring the activity of ... Cancer is a disease of mutation, and the most commonly mutated

26 Jul 2024: a downstream conduit for many (perhaps all) oncogenic growth signals, and a second mouse that models pharmacological restoration of the p53 tumour suppressor, which is functionally inactivated in most human cancers. ... 2011). Validation of MdmX as a

21 Jul 2023: Alan Fersht. Tumour suppressor p53 structure and drug discovery. Alan Fersht was a Natural Sciences undergraduate and Chemistry postgraduate at Gonville and Caius from 1962-68. ... Cancer is a disease of mutation, and the most commonly mutated protein by

24 Jul 2024: Chiba Ene (PhD Medical Sciences) - Histone demethylase Jumonji D3 (JMJD3) as a Tumor Suppressor by Regulating p53 Activity through Lysine Demethylation.

26 Jan 2021: Cancer is a disease of mutation, and the most commonly mutated protein by far is the tumour suppressor p53. ... Tumour Suppressor p53. Structural Biology and Drug Discovery. Alan Fersht. MRC Laboratory of Molecular Biology.

26 Jul 2024: The net result is hyperplasia in several tissues, which is exacerbated by the additional loss of the tumour suppressor protein p53. ... p53 is non-functional in the majority of human tumours and mice lacking p53 are prone to tumour development.

25 Jul 2024: His work is now focussed on how mutation affects proteins in the cell cycle, particularly the tumour suppressor p53 – the so-called “Guardian of the Genome” – in order to design novel

Alan rejoined the LMB in 2010, where he continued his work on protein folding, misfolding and disease, concentrating on the tumour suppressor p53 until the end of 2017. ... n. Cancer is a disease of mutation, and the most commonly mutated protein by far

23 Feb 2024: For example, we recently showed that hPSCs recurrently acquire cancer-associated mutations in the tumour suppressor TP53 (p53) that promote growth in culture and would increase the risk of cancer formation

26 Jul 2024: During the conference the Prof. Karen Vousden from The Crick Institute, London, was awarded of the CDD Award 2018 for her pioneering studies on the function of the tumour suppressor protein ... p53 in the response to environmental stressors.

20 May 2024: Alan Fersht - Tumour suppressor p53 structure and drug discovery.

Toggle navigation. Go. Tumor suppressor p53 fragments. Superfamily. Families. Domains. 1.

23 Feb 2024: For example, hPSCs recurrently acquire cancer-associated mutations in the tumour suppressor TP53 (p53) that promote growth in culture and would increase the risk of cancer formation from transplanted cells (Merkle ... Human pluripotent stem cells

21 Jul 2023: Tumour suppressor p53 structure and drug discovery. LMB Division - Protein and Nucleic Acid Chemistry.

can bind to and deactivate an enzyme that controls the stability of the p53 tumour suppressor protein. ... This deactivation allows p53 to be turned on, putting the brakes on cancer growth.

{"id":61,"date":"2012-06-25T10:03:42","date_gmt":"2012-06-25T10:03:42","guid":{"rendered":"http://www2.mrc-lmb.cam.ac.uk/wordpress/?page_id=61"},"modified":"2024-05-20T14:39:16","modified_gmt":"2024-05-20T13:39:16","slug":"protein-and-nucleic-acid-ch

nAlan will continue to lead his research on the p53 tumour suppressor protein at the LMB with an MRC programme grant for the next five years.

Toggle navigation. Go. p53 DNA-binding domain-like. Domain. Species. Proteins. 2. 49.

n. Professor Sir Alan Fersht, FRS, from the PNAC Division of LMB, has been awarded an Advanced ERC Grant of u20ac1.5m for his project u201cTumour suppressor p53: structure, stability and ... 70% of human cancers have p53 directly inactivated by mutation.

20 Oct 2017: can bind to and deactivate an enzyme that controls the stability of the p53 tumour suppressor protein. ... This deactivation allows p53 to be turned on, putting the brakes on cancer growth.

25 Jul 2024: Search site. Publications. Uploading Images. Members of the Department can attach an image to a publication by clicking on the title of the publication in the listing below. Please note: all images attached to a publication will be visible on

{"id":18741,"date":"2020-08-04T17:10:07","date_gmt":"2020-08-04T16:10:07","guid":{"rendered":"https://www2.mrc-lmb.cam.ac.uk/?p=18741"},"modified":"2020-08-04T17:10:09","modified_gmt":"2020-08-04T16:10:09","slug":"alan-fersht-and-marta-zlatic-win-roy

23 Feb 2024: 2009) NPM-ALK modulates the p53 tumour suppressor pathway in a JNK and PI 3-Kinase dependent manner: MDM-2 is a potential therapeutic target for the treatment of ALK-expressing ... Merkel, O., Morrigl, R.,Turner, S.D. and Kenner, L. (2017) When the

Toggle navigation. Go. Peptides. Fold. Superfamilies. Families. 1. 2. 1. 3. 1. 8. 1. 5. 1. 2. 1. 1. 3. 3. 1. 1. 7. 7. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 2. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 7. 1. 2.

24 Sep 2010: Alan will continue to lead his research on the p53 tumour suppressor protein at the LMB with an MRC programme grant for the next five years.

4 Aug 2020: Alan’s most recent interest is in the tumour suppressor p53, with the aim to understand how mutations affect its function, so that novel anti-cancer drugs may be designed to

26 Nov 2010: Professor Sir Alan Fersht, FRS, from the PNAC Division of LMB, has been awarded an Advanced ERC Grant of 1.5m for his project “Tumour suppressor p53: structure, stability and novel ... Alan’s grant complements his MRC programme grant on the

29 Nov 2011: T. M. Rippin, TH. Mechanistic studies of the tumour suppressor p53: a basis for rational anti-cancer drug design. ... Stability, folding and evolution of the tumour suppressor protein p16. L.

29 Nov 2011: A. N. Bullock, CTH. The destabilising effects of tumorigenic P53 mutations. ... J. Henckel, CAI. Macromolecular interactions of the tumor suppressor P53. M.

cluster_id panther_id cluster_name knownness num_proteins num_species best_known_protein_id best_known_protein_gene best_known_protein_name key_protein_ids key_protein_xrefs UKP00821 PTHR47953 OS08G0105600 PROTEIN 0.0 581 26 K7VM54_MAIZE 103640324

31 Oct 2013: The protein suppressor p53 is one ofthe most important proteins in the cell,being implicated in processes from fer-tility to ageing. ... p53 inactive simply make it less stable,and start melting at body temperatureor below.’.

13 Dec 2016:

cluster_id panther_id cluster_name knownness num_proteins num_species best_known_protein_id best_known_protein_gene best_known_protein_name key_protein_ids key_protein_xrefs UKP04564 PTHR33498 UKP04564 0.0 33 8 Q2FW90_STAA8 SAOUHSC_01993 Transposase,

A microRNA componentof the p53 tumour suppressor network. Nature.2007;447(7148):1130-1134. 39. Raver-Shapira N, Marciano E, Meiri E, et al. ... Chang TC, Wentzel EA, Kent OA, et al. Transacti-vation of miR-34a by p53 broadly influences geneexpression and

3 Oct 2016: Example - Definition. The P53/Mdm2 DNA-damage repair mechanism. P53 is a tumor suppressor protein that is activated in reply to DNAdamage. ... P53 can thuseither repair DNA damage or provoke apoptosis. Boolean Model, in Biocham:.

The p53 tumour suppressor is a transcription factor that regulatesthe progression of the cell through its cycle and cell death(apoptosis) in response to environmental stimuli such as DNAdamage and ... Thus, incontrast to p53, p63 is essential for several

13 Dec 2016: 109635 sf a.2.14 - DnaK suppressor protein DksA, alpha-hairpin domain L 111283 sf d.283.1 - Putative modulator of DNA gyrase, PmbA/TldD L 111304 sf e.49.1 - ... 58744 sf j.69.1 - Tumor suppressor p53 fragments NONA 58749 sf j.70.1 - FxFG nucleoporin

10 Aug 2004: Technical ReportNumber 597. Computer Laboratory. UCAM-CL-TR-597ISSN 1476-2986. Syntactic simplification and textcohesion. Advaith Siddharthan. August 2004. 15 JJ Thomson Avenue. Cambridge CB3 0FD. United Kingdom. phone 44 1223 763500.

11 Sep 2003: Wang et al., 2000);barstar (Schreiber et al., 1994); and p53 (Nikolova et al.,1998). ... P., and Fersht, A. R. (1998)Semirational Design of Active Tumor Suppressor p53 DNABinding Domain with Enhanced Stability,Proc.

16 Sep 2003: 13. Tang KS, Fersht AR, Itzhaki LS: Sequential unfolding of ankyrinrepeats in tumor suppressor p16. ... Protein Sci 2001,10:2123-2130. 25. Nikolova PV, Wong KB, DeDecker B, Henckel J, Fersht AR:Mechanism of rescue of common p53 cancer mutations

4 Oct 2021: Legend. Integrated Mitochondrial Protein Index (IMPI) [2021Q4pre-20211001]. Sheets:. 1) Table Legend. 2) IMPI All Human Genes (Ensembl): All human genes with annotation, curation and IMPI localisation score. Ensembl Gene ID: Gene identifier for

11 Nov 2011: Notices:Calendar 978Noticeof abenefaction 978GovernmentHigherEducationWhitePaper:. Notice 978BallotsonGraces6–13of 26May2011and. Grace3of 15June2011:Notice 978Vacancies, appointments, etc.:. VacanciesintheUniversity 979CRASSHFellowshipCompetitions,

14 Aug 2023: May 2020. The Bio Revolution: Innovations transforming econom. ies, societies, and our lives. The Bio RevolutionInnovations transforming economies, societies, and our lives. McKinsey Global Institute. Since its founding in 1990, the McKinsey Global

11 Mar 2009: Figure 6 Changes in protein stability produced by observed mutations. Changes in protein stability produced by engineered mutations that mimic native mutationsseen in barnase [29], p53 [31] and GroEL [32]. ... its mutation back to the consensus residue